Progesterone Archives - Revista Brasileira de Ginecologia e Obstetrícia
Summary
Revista Brasileira de Ginecologia e Obstetrícia. 1998;20(2):91-95
DOI 10.1590/S0100-72031998000200006
Predicting pregnancy outcome from one or more maternal serum factors has been the subject of numerous investigations with controversial results. The aim of this study was to evaluate the serum levels of CA-125, CA-19.9, CA-15.3, beta-hCG, estradiol, progesterone, alpha-fetoprotein and CEA in women with abortion (n=18) and with pregnancy complicated by bleeding (n=6), in comparison to the serum levels of the control group (n=7). The results showed that the serum levels of CA-125 were significantly increased in the abortion group (153.9 ± 43.3 IU/ml), but no difference was detected in pregnancy complicated by bleeding (17.4 ± 2.6 IU/ml), as compared to control (24.7 ± 13.4 IU/ml). However, high serum levels of CA-19.9 were found in the group with pregnancy complicated by bleeding in comparison with the abortion group (20.2 ± 11.4 IU/ml versus 6.6 ± 1.4 IU/ml, respectively). In relation to hormone serum levels, both, the abortion (17.38 ± 9.4 ng/ml) and bleeding (18.3 ± 8.9 ng/ml) groups showed lower serum levels of progesterone, as compared to control (60.4 ± 26.8 ng/ml). Besides, women with abortion had additional low estradiol serum levels, when compared to controls (1,327 ± 1,015 ng/ml versus 10,774 ± 9,244 ng/ml). It was concluded that the serum levels of progesterone, CA-19.9 and beta-hCG seem to add valuable information to the evaluation of a pregnancy complicated by bleeding.
Summary
Revista Brasileira de Ginecologia e Obstetrícia. 1998;20(2):91-95
DOI 10.1590/S0100-72031998000200006
Predicting pregnancy outcome from one or more maternal serum factors has been the subject of numerous investigations with controversial results. The aim of this study was to evaluate the serum levels of CA-125, CA-19.9, CA-15.3, beta-hCG, estradiol, progesterone, alpha-fetoprotein and CEA in women with abortion (n=18) and with pregnancy complicated by bleeding (n=6), in comparison to the serum levels of the control group (n=7). The results showed that the serum levels of CA-125 were significantly increased in the abortion group (153.9 ± 43.3 IU/ml), but no difference was detected in pregnancy complicated by bleeding (17.4 ± 2.6 IU/ml), as compared to control (24.7 ± 13.4 IU/ml). However, high serum levels of CA-19.9 were found in the group with pregnancy complicated by bleeding in comparison with the abortion group (20.2 ± 11.4 IU/ml versus 6.6 ± 1.4 IU/ml, respectively). In relation to hormone serum levels, both, the abortion (17.38 ± 9.4 ng/ml) and bleeding (18.3 ± 8.9 ng/ml) groups showed lower serum levels of progesterone, as compared to control (60.4 ± 26.8 ng/ml). Besides, women with abortion had additional low estradiol serum levels, when compared to controls (1,327 ± 1,015 ng/ml versus 10,774 ± 9,244 ng/ml). It was concluded that the serum levels of progesterone, CA-19.9 and beta-hCG seem to add valuable information to the evaluation of a pregnancy complicated by bleeding.
Summary
Revista Brasileira de Ginecologia e Obstetrícia. 1998;20(9):533-536
DOI 10.1590/S0100-72031998000900007
Purpose: to evaluate the effects of tamoxifen (TAM) on plasma levels of estradiol, progesterone, prolactin, luteinizing hormone (LH), follicle-stimulating hormone (FSH) and steroid hormone-binding globulin (SHBG) when given to premenopausal women in the doses of 10 and 20 mg/day for 22 days. Patients and Methods: a randomized double-blind study was performed with 43 premenopausal eumenorrheic women. The patients were divided into three groups: A (N = 15, placebo); B (N = 15, TAM 10 mg/day) and C (N = 13, 20 mg/day). They started taking an oral dose of TAM or placebo on the very first day of the menstrual cycle. Two hormone determinations were performed, both on the 22nd day of the menstrual cycle: the first in the cycle that preceded the use of the drug and the second, in the following cycle, after 22 days of using the medication. We used the Levine and Student tests in order to evaluate the homogeneity of the sample and the variation of the hormone determinations respectively. Results:serum levels of estradiol, progesterone and SHBG increased significantly in groups B and C. In group C, we also observed increase in serum level of FSH (p < 0.0045) and a fall in prolactin level (p < 0.0055). Conclusions: TAM promoted a significant increase in serum concentrations of estradiol, progesterone and SHBG either in the doses of 10 or 20 mg/day. However, significant increase in FSH and decrease in prolactin were obtained only with the dose of 20 mg/day.
Summary
Revista Brasileira de Ginecologia e Obstetrícia. 1998;20(9):533-536
DOI 10.1590/S0100-72031998000900007
Purpose: to evaluate the effects of tamoxifen (TAM) on plasma levels of estradiol, progesterone, prolactin, luteinizing hormone (LH), follicle-stimulating hormone (FSH) and steroid hormone-binding globulin (SHBG) when given to premenopausal women in the doses of 10 and 20 mg/day for 22 days. Patients and Methods: a randomized double-blind study was performed with 43 premenopausal eumenorrheic women. The patients were divided into three groups: A (N = 15, placebo); B (N = 15, TAM 10 mg/day) and C (N = 13, 20 mg/day). They started taking an oral dose of TAM or placebo on the very first day of the menstrual cycle. Two hormone determinations were performed, both on the 22nd day of the menstrual cycle: the first in the cycle that preceded the use of the drug and the second, in the following cycle, after 22 days of using the medication. We used the Levine and Student tests in order to evaluate the homogeneity of the sample and the variation of the hormone determinations respectively. Results:serum levels of estradiol, progesterone and SHBG increased significantly in groups B and C. In group C, we also observed increase in serum level of FSH (p < 0.0045) and a fall in prolactin level (p < 0.0055). Conclusions: TAM promoted a significant increase in serum concentrations of estradiol, progesterone and SHBG either in the doses of 10 or 20 mg/day. However, significant increase in FSH and decrease in prolactin were obtained only with the dose of 20 mg/day.
Summary
Revista Brasileira de Ginecologia e Obstetrícia. 1998;20(5):273-280
DOI 10.1590/S0100-72031998000500007
An open-label comparative study was conducted in nine centers in Brazil to evaluate the tolerability and cycle control of two low-dose oral contraceptives containing 20 mg ethynylestradiol/75 mg gestodene and 20 mg ethynylestradiol/150 mg desogestrel, during six treatment cycles. A total of 167 healthy sexually active women were enrolled (77 in the gestodene group and 90 in the desogestrel group) and 138 completed the six-cycle treatment period. A lipid and hemostatic profile was performed for a subgroup of first users. A total of 867 cycles were evaluated. Irregular bleeding did not occur in 95.4% of the cycles evaluated with gestodene and in 91.9% with desogestrel. Tolerability was good with both preparations but there was significantly more nausea in the desogestrel group. Cycle control was good with both preparations with a significantly lower incidence of irregular bleeding with gestodene when all cycles were considered. There were no clinically significant changes in the hemostatic profile. Lipid profile showed a trend to be more favorable after six cycles of treatment with both preparations. Women in the gestodene group did not present changes in the mean weight; in the desogestrel group there was a significant mean weight increase of 1 kg after six cycles of treatment. Compliance with treatment was good with both preparations. Results of this study demonstrated that low-dose preparations containing gestodene or desogestrel combined with 20 mg of ethynylestradiol are well-tolerated oral contraceptives that provide good cycle control.
Summary
Revista Brasileira de Ginecologia e Obstetrícia. 1998;20(5):273-280
DOI 10.1590/S0100-72031998000500007
An open-label comparative study was conducted in nine centers in Brazil to evaluate the tolerability and cycle control of two low-dose oral contraceptives containing 20 mg ethynylestradiol/75 mg gestodene and 20 mg ethynylestradiol/150 mg desogestrel, during six treatment cycles. A total of 167 healthy sexually active women were enrolled (77 in the gestodene group and 90 in the desogestrel group) and 138 completed the six-cycle treatment period. A lipid and hemostatic profile was performed for a subgroup of first users. A total of 867 cycles were evaluated. Irregular bleeding did not occur in 95.4% of the cycles evaluated with gestodene and in 91.9% with desogestrel. Tolerability was good with both preparations but there was significantly more nausea in the desogestrel group. Cycle control was good with both preparations with a significantly lower incidence of irregular bleeding with gestodene when all cycles were considered. There were no clinically significant changes in the hemostatic profile. Lipid profile showed a trend to be more favorable after six cycles of treatment with both preparations. Women in the gestodene group did not present changes in the mean weight; in the desogestrel group there was a significant mean weight increase of 1 kg after six cycles of treatment. Compliance with treatment was good with both preparations. Results of this study demonstrated that low-dose preparations containing gestodene or desogestrel combined with 20 mg of ethynylestradiol are well-tolerated oral contraceptives that provide good cycle control.
Summary
Revista Brasileira de Ginecologia e Obstetrícia. 1998;20(6):309-313
DOI 10.1590/S0100-72031998000600003
Objective: to evaluate variations in body weight, arterial blood pressure, fasting glucose, HbA1C, insulin, total cholesterol, HDL-C, LDL-C, triglycerides, Sgot, SGPT, GGT and bilirubin in women bearing a single subdermal Silastic implant containing 55 mg (+ 10%) of nomegestrol acetate during two years. Methods: eighteen healthy volunteers of reproductive age who desired to use anticonceptive drugs and who did not present contraindications to hormonal contraception participated in the study. All women were investigated before starting treatment and were followed-up for two years. At the end of the first year the capsules were inserted. Results: body weight increased from 54.9 + 1.5 kg at admission to 55.3 + 2.0 kg at 12 months of use (p<0.05) and from 56.0 + 2.7 kg at 24 months of use. There was a slight increase in arterial blood pressure, both systolic and diastolic, at month 12 (p<0.01). At month 24, the arterial blood pressure was not significantly different from the values at admission. All values were within the normal range. Insulin, HbA1C, LDL-C and GGT remained unchanged during the use of the implant. A significant decrease in total cholesterol (p<0.05) was observed in the third month and of HDL-C (p<0.01) in the sixth month. All lipoprotein alterations were inconsistent and values were within the normal range. Significant increases in fast glucose (p<0.05 and p<0.01) were observed in the third and sixth months, respectively. Significant SGOT decreases (p<0.05, p<0.01 and p<0.05) were observed in months 6, 18 and 24, respectively, and of SGPT (p<0.05) in month 18. Significant bilirubin increase (p<0.05) was observed only in the third month of implant use. All these variations remained within the normal range. Conclusions: these results show that, within the normal range, fasting glucose variations do not correlate with alterations in insulin levels. The slight serum lipoprotein, SGTO, SGPT and insulin alterations were transient. No clinical effects could be observed regarding lipoproteins, carbohydrate metabolism, insulin levels and liver function among the users during the two years.
Summary
Revista Brasileira de Ginecologia e Obstetrícia. 1998;20(6):309-313
DOI 10.1590/S0100-72031998000600003
Objective: to evaluate variations in body weight, arterial blood pressure, fasting glucose, HbA1C, insulin, total cholesterol, HDL-C, LDL-C, triglycerides, Sgot, SGPT, GGT and bilirubin in women bearing a single subdermal Silastic implant containing 55 mg (+ 10%) of nomegestrol acetate during two years. Methods: eighteen healthy volunteers of reproductive age who desired to use anticonceptive drugs and who did not present contraindications to hormonal contraception participated in the study. All women were investigated before starting treatment and were followed-up for two years. At the end of the first year the capsules were inserted. Results: body weight increased from 54.9 + 1.5 kg at admission to 55.3 + 2.0 kg at 12 months of use (p<0.05) and from 56.0 + 2.7 kg at 24 months of use. There was a slight increase in arterial blood pressure, both systolic and diastolic, at month 12 (p<0.01). At month 24, the arterial blood pressure was not significantly different from the values at admission. All values were within the normal range. Insulin, HbA1C, LDL-C and GGT remained unchanged during the use of the implant. A significant decrease in total cholesterol (p<0.05) was observed in the third month and of HDL-C (p<0.01) in the sixth month. All lipoprotein alterations were inconsistent and values were within the normal range. Significant increases in fast glucose (p<0.05 and p<0.01) were observed in the third and sixth months, respectively. Significant SGOT decreases (p<0.05, p<0.01 and p<0.05) were observed in months 6, 18 and 24, respectively, and of SGPT (p<0.05) in month 18. Significant bilirubin increase (p<0.05) was observed only in the third month of implant use. All these variations remained within the normal range. Conclusions: these results show that, within the normal range, fasting glucose variations do not correlate with alterations in insulin levels. The slight serum lipoprotein, SGTO, SGPT and insulin alterations were transient. No clinical effects could be observed regarding lipoproteins, carbohydrate metabolism, insulin levels and liver function among the users during the two years.
Summary
Revista Brasileira de Ginecologia e Obstetrícia. 2006;28(11):643-651
DOI 10.1590/S0100-72032006001100003
PURPOSE: literature reports show that there are no conclusive data about the association between endometriosis and the concentrations of hormones involved in the control of reproduction. Thus, the present study was undertaken to determine FSH, LH, estradiol (E), progesterone (P), and histamine (Hi) concentrations in serum, peritoneal fluid and follicular fluid of women with and without endometriosis. METHODS: the extent of the disease was staged according to the revised American Fertility Society classification (1997). For the collection of serum and peritoneal fluid, 28 women with endometriosis undergoing diagnostic laparoscopy were selected (18 infertile women with endometriosis I-II and ten infertile women with endometriosis III-IV). For the control group, 21 fertile women undergoing laparoscopy for tubal sterilization were selected. Follicular fluid was obtained from 39 infertile women undergoing in vitro fertilization (21 women with endometriosis and 18 women without endometriosis). RESULTS: FSH and LH levels in serum, peritoneal fluid and follicular fluid did not differ significantly between groups. On the other hand, E and P concentrations in the peritoneal fluid were significantly lower in infertile women with endometriosis (E: 154.2±15.3 for stages I-II and 89.3 ng/mL±9.8 ng/mL for stages III-IV; P: 11.2±1.5 for stages I-II and 7.6 ng/mL±0.8 for stages III-IV) in comparison with control women (E: 289.1 ng/mL±30.1; P: 32.8±4.1 ng/mL) (Kruskal-Wallis/Dunn tests; p<0.05). In serum, estradiol and progesterone concentrations followed the same pattern. In the follicular fluid, E and Hi concentrations were significantly lower in women with endometriosis (E: 97.4±11.1 pg/mL; Hi: 6.6±0.9 ng/mL) in comparison to women without endometriosis (E: 237.5±28.5 pg/mL; Hi: 13.8±1.3 ng/mL) (Student t-test; p<0.05), while progesterone levels revealed no significant difference between groups. CONCLUSIONS: our results indicate ovary dysfunction in women with endometriosis, with reduction on E, P and Hi concentrations, which may contribute to the subfertility often associated with the disease.
Summary
Revista Brasileira de Ginecologia e Obstetrícia. 2006;28(11):643-651
DOI 10.1590/S0100-72032006001100003
PURPOSE: literature reports show that there are no conclusive data about the association between endometriosis and the concentrations of hormones involved in the control of reproduction. Thus, the present study was undertaken to determine FSH, LH, estradiol (E), progesterone (P), and histamine (Hi) concentrations in serum, peritoneal fluid and follicular fluid of women with and without endometriosis. METHODS: the extent of the disease was staged according to the revised American Fertility Society classification (1997). For the collection of serum and peritoneal fluid, 28 women with endometriosis undergoing diagnostic laparoscopy were selected (18 infertile women with endometriosis I-II and ten infertile women with endometriosis III-IV). For the control group, 21 fertile women undergoing laparoscopy for tubal sterilization were selected. Follicular fluid was obtained from 39 infertile women undergoing in vitro fertilization (21 women with endometriosis and 18 women without endometriosis). RESULTS: FSH and LH levels in serum, peritoneal fluid and follicular fluid did not differ significantly between groups. On the other hand, E and P concentrations in the peritoneal fluid were significantly lower in infertile women with endometriosis (E: 154.2±15.3 for stages I-II and 89.3 ng/mL±9.8 ng/mL for stages III-IV; P: 11.2±1.5 for stages I-II and 7.6 ng/mL±0.8 for stages III-IV) in comparison with control women (E: 289.1 ng/mL±30.1; P: 32.8±4.1 ng/mL) (Kruskal-Wallis/Dunn tests; p<0.05). In serum, estradiol and progesterone concentrations followed the same pattern. In the follicular fluid, E and Hi concentrations were significantly lower in women with endometriosis (E: 97.4±11.1 pg/mL; Hi: 6.6±0.9 ng/mL) in comparison to women without endometriosis (E: 237.5±28.5 pg/mL; Hi: 13.8±1.3 ng/mL) (Student t-test; p<0.05), while progesterone levels revealed no significant difference between groups. CONCLUSIONS: our results indicate ovary dysfunction in women with endometriosis, with reduction on E, P and Hi concentrations, which may contribute to the subfertility often associated with the disease.
Summary
Revista Brasileira de Ginecologia e Obstetrícia. 2005;27(9):529-533
DOI 10.1590/S0100-72032005000900005
PURPOSE: to study the histological modifications that occur in the endometrium of women before and six months after tubal ligation (TL) and to correlate these findings with progesterone (P4) levels. METHODS: the study was conducted on 16 women with normal menstrual cycles who were evaluated before and in the sixth cycle after TL. P4 levels were determined from the 8th day at 2-day intervals until ovulation and on the 8th, 10th and 12th day after ovulation or on the 24th day of the cycle. An endometrial biopsy was obtained between the 10th and 12th day after ovulation or on the 24th day of the cycle and a correlation with P4 was determined. Data were analyzed statistically by the nonparametric McNemar test for the evaluation of hormonal determination and by the exact Fisher test for the histological evaluation of the endometrium, with the level of significance set at p<0.05. RESULTS: mean age was 34.1±1.3 years. The intermenstrual interval was 27.1±2.6 days and the duration of bleeding was 3 to 5 days, with no difference between the studied periods. Before TL, 8/16 (50.0%) of the cases had a secretory endometrium according to the cycle, 3/16 (18.8%) had a secretory endometrium not according to the cycle and 3/16 (18.8%) had a dysfunctional endometrium, suggesting a defect in the luteal phase in 6/16 (37.5%). After TL, 7/16 (43.8%) had a secretory endometrium according to the cycle, 3/16 (18.8%) a secretory endometrium not according to the cycle and 4/16 (25.0%) had a dysfunctional endometrium, suggesting a defect in the luteal phase in 7/16 (43.8%). In 2/16 (12.5%) of the cases before TL and in 2/16 (12.5%) other cases after TL it was not possible to perform histological evaluation due to insufficient material or unspecfiic endometritis. In the luteal phase after TL, mean P4 levels were significantly lower on days +8, +10 and +12 than before TL, being 15.1, 18.0 and 20.7 ng/ml, respectively, before TL and 10.6, 8.0 and 5.4 ng/ml after TL (p<0.05). Before TL, 5/8 (62.5%) of the cases with a secretory endometrium according to the cycle had P4 >10 ng/ml and 3/8 (37.5%) had P4 <10 ng/ml. After TL, when the endometrium was secretory according to the cycle, P4 was >10 ng/ml in 4/7 (57.1%) and <10 ng/ml in 3/7 (42.9%). These differences were nonsignificant (p>0.05). CONCLUSION: six months after TL, the intermenstrual interval and the duration of bleeding were unchanged. P4 levels decreased during the luteal phase although this did not interfere in the endometrial response.
Summary
Revista Brasileira de Ginecologia e Obstetrícia. 2005;27(9):529-533
DOI 10.1590/S0100-72032005000900005
PURPOSE: to study the histological modifications that occur in the endometrium of women before and six months after tubal ligation (TL) and to correlate these findings with progesterone (P4) levels. METHODS: the study was conducted on 16 women with normal menstrual cycles who were evaluated before and in the sixth cycle after TL. P4 levels were determined from the 8th day at 2-day intervals until ovulation and on the 8th, 10th and 12th day after ovulation or on the 24th day of the cycle. An endometrial biopsy was obtained between the 10th and 12th day after ovulation or on the 24th day of the cycle and a correlation with P4 was determined. Data were analyzed statistically by the nonparametric McNemar test for the evaluation of hormonal determination and by the exact Fisher test for the histological evaluation of the endometrium, with the level of significance set at p<0.05. RESULTS: mean age was 34.1±1.3 years. The intermenstrual interval was 27.1±2.6 days and the duration of bleeding was 3 to 5 days, with no difference between the studied periods. Before TL, 8/16 (50.0%) of the cases had a secretory endometrium according to the cycle, 3/16 (18.8%) had a secretory endometrium not according to the cycle and 3/16 (18.8%) had a dysfunctional endometrium, suggesting a defect in the luteal phase in 6/16 (37.5%). After TL, 7/16 (43.8%) had a secretory endometrium according to the cycle, 3/16 (18.8%) a secretory endometrium not according to the cycle and 4/16 (25.0%) had a dysfunctional endometrium, suggesting a defect in the luteal phase in 7/16 (43.8%). In 2/16 (12.5%) of the cases before TL and in 2/16 (12.5%) other cases after TL it was not possible to perform histological evaluation due to insufficient material or unspecfiic endometritis. In the luteal phase after TL, mean P4 levels were significantly lower on days +8, +10 and +12 than before TL, being 15.1, 18.0 and 20.7 ng/ml, respectively, before TL and 10.6, 8.0 and 5.4 ng/ml after TL (p<0.05). Before TL, 5/8 (62.5%) of the cases with a secretory endometrium according to the cycle had P4 >10 ng/ml and 3/8 (37.5%) had P4 <10 ng/ml. After TL, when the endometrium was secretory according to the cycle, P4 was >10 ng/ml in 4/7 (57.1%) and <10 ng/ml in 3/7 (42.9%). These differences were nonsignificant (p>0.05). CONCLUSION: six months after TL, the intermenstrual interval and the duration of bleeding were unchanged. P4 levels decreased during the luteal phase although this did not interfere in the endometrial response.